Introducing LIVTENCITY ▼(maribavir) to your MDT

These ‘talking head’ videos have been created using content from the April 2024 Transplant Exchange Online webinar for on-demand viewing.

An introduction to LIVTENCITY (maribavir)

In this video, Dr Sowsan Atabani discusses data from the SOLSTICE study, which was designed to investigate the efficacy and safety of LIVTENCITY compared to investigator assigned therapy in stem cell or solid organ recipients with CMV infection.

LIVTENCITY (maribavir) and healthcare resource utilisation

In this video, Dr Adnan Sharif explores the healthcare utilisation costs associated with post-transplant CMV, especially in the context of refractory and resistant CMV.

Current treatments in post-transplant CMV infections and case studies

In this video, Janette Chu explores current treatment options in post-transplant CMV infections, along with two patient case studies who were treated with LIVTENCITY.

Panel discussion

In this video, our panel discuss interesting statistics obtained from poll questions ran during the webinar, as well as answering your questions on administration, monitoring and refractory CMV thresholds of LIVTENCITY and more.